Funding for this research was provided by:
Swedish state under the ALF-agreement (ALFGBG-715781, ALFGFG-784921)
Svenska Läkaresällskapet (SLS-881501)
Svenska Sällskapet för Medicinsk Forskning (S18-0040)
Linnéa och Josef Carlssons Stiftelse (90_20180321_048)
Stiftelsen Promobilia (18012)
Göteborgs Läkaresällskap (GLS-780651)
Magnus Bergvalls Stiftelse (2017-01990)
University of Gothenburg
Article History
Received: 12 April 2022
Revised: 8 July 2022
Accepted: 8 July 2022
First Online: 19 July 2022
Declarations
:
: Dr. Karlander reports no conflict of interests, Dr. Ljungqvist reports no conflict of interests, Dr. Sörbo reports no conflict of interests, Dr. Zelano has been a speaker (honoraria) at non-branded educations organized by UCB and Eisai and as an employee of Sahlgrenska University Hospital (no personal compensation) investigator in clinical trials sponsored by UCB, SK life science, Bial, and GW Pharma.
: The study was approved by the Ethical Review Authority (approval number 612-18). Data were anonymized by the National Board of Health and Welfare.